Taken together, these results suggest that IMCY-0098 dose C modulates immune response in T1D by promoting the generation of treatment-specific cytolytic CD4+ T cells and inhibiting pathogenic autoreactive CD8+ T cells. This evidence concerns the gene CD8A and type 1 diabetes mellitus.